Overview
Osimertinib is a breakthrough third-generation EGFR tyrosine kinase inhibitor developed by AstraZeneca. It received FDA approval in 2015 for the treatment of metastatic EGFR T790M mutation-positive non-small cell lung cancer (NSCLC). The drug represents a significant advancement in targeted cancer therapy, specifically designed to overcome resistance mutations that develop after first-line EGFR-TKI treatment. As a covalent inhibitor, osimertinib binds irreversibly to the EGFR kinase domain, particularly effective against both common EGFR mutations and the T790M resistance mutation. Its development marked a turning point in NSCLC treatment, offering hope for patients with acquired resistance to earlier generation EGFR inhibitors.
Physical and Chemical Properties
Osimertinib appears as a white to off-white crystalline powder with moderate solubility in organic solvents like DMSO but limited water solubility. The compound's molecular structure contains a pyrimidine core with substituted amino and acrylamide groups that enable its selective binding to mutant EGFR forms. The drug's stability profile requires protection from light and moisture, with recommended storage at refrigerated temperatures (2-8°C) for long-term preservation. Its lipophilic nature contributes to good cellular permeability, while the acrylamide moiety facilitates covalent binding to cysteine-797 in the EGFR kinase domain, accounting for its irreversible inhibition mechanism.
Main Applications
Osimertinib is primarily indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in patients with EGFR T790M mutation, either as second-line therapy after progression on first-generation EGFR-TKIs or as first-line treatment for EGFR mutation-positive cases. It has shown superior progression-free survival compared to earlier EGFR inhibitors. Recent clinical trials have expanded osimertinib's applications to include adjuvant therapy after tumor resection in EGFR mutation-positive NSCLC patients. Additionally, research is exploring its potential in treating CNS metastases due to its ability to cross the blood-brain barrier more effectively than previous EGFR-TKIs.
Safety and Storage
Osimertinib carries several important safety considerations, including risk of interstitial lung disease/pneumonitis (occurring in approximately 4% of patients), QTc interval prolongation, and cardiomyopathy. Regular monitoring of cardiac function and pulmonary status is recommended during treatment. Proper storage requires protection from light and moisture at controlled temperatures (2-8°C). The drug substance should be handled with appropriate personal protective equipment due to its potent biological activity. Stability studies indicate the compound remains stable for at least 24 months when stored under recommended conditions in the original packaging.
B2B Procurement Guide
Pharmaceutical companies sourcing osimertinib API should verify suppliers' GMP compliance and request comprehensive documentation including Certificate of Analysis, DMF references, and stability data. Given the high value of the material, consider suppliers with robust quality systems and audit history. Procurement professionals should establish cold chain logistics for transport and storage, with temperature monitoring throughout the supply chain. Market intelligence suggests the API price fluctuates based on production scale and purity specifications, with typical lead times of 8-12 weeks for GMP-grade material. Consider dual sourcing strategies to mitigate supply risks for this critical oncology drug.